Legal Representation
Attorney
Kaushal Odedra
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 4, 2025 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Aug 4, 2025 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Apr 9, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Apr 9, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Mar 28, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 17, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 17, 2025 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 17, 2025 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jan 6, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jan 6, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 19, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Oct 19, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Apr 23, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 4, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 27, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 7, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 7, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 22, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 17, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 15, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 22, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for treatment of autoimmune and inflammatory diseases; Pharmaceutical preparations comprised of a monoclonal antibody to a tumor necrosis factor alpha for treatment of autoimmune and inflammatory diseases
First Use Anywhere:
20240100
First Use in Commerce:
20240100
Additional Information
Pseudo Mark
HULIO THREE HUNDRED SIXTY; HULIO THREE SIX ZERO; HULIO THREE SIXTY
Classification
International Classes
005